Introduction to Coronavirus (COVID-19) Antibody Discovery by Premade Human Antibody Library

Since the outbreak of COVID-19, it has caused extremely serious harm all over the world. Since COVID-19 can be spread through droplet transmission and behaviors such as coughing, sneezing, breathing, singing, or talking by carriers can lead to the spread of the disease, OCVID-19 has an extremely high rate of transmission. In the early stages of COVID-19 outbreaks, it is extremely infectious and lethal, killing many people. The disease can cause multiple organ damage, the most severe of which is in the lungs. Although the virulence of the virus has now been drastically reduced, it is still present and can cause damage to the organism. Therefore, diagnostic and therapeutic measures against COVID-19 are important. Currently, antibodies play an important role in disease detection, diagnosis, and treatment. Therefore, the establishment of targeted antibody drug discovery services, such as anti-disease-specific target antibodies and antibody discovery for immunotherapy, is particularly important for disease control. Based on our rich field experience and advanced research platform, Creative Biolabs provides comprehensive services to support premade antibody library screening and coronavirus (COVID-19) antibody discovery.

Coronavirus (COVID-19) Antibody Discovery

COVID-19 has an extremely high morbidity, transmission rate, and mortality. And COVID-19-specific antibodies can play an important role in the detection, diagnosis, and treatment of COVID-19. When a virus invades the human body, the body produces specific antibodies for defense, of which the specific antibody IgM is the first to be produced for early defense, followed by the production of IgG antibodies. Serologic testing is used to indirectly determine the presence or absence of the virus and the status of the virus infection by detecting the presence and level of the specific antibodies IgM and IgG in blood samples. At the same time, the antibodies in the patient's body are the most direct and promising candidate for the treatment of COVID-19. This is the fastest way to alleviate or even conquer the COVID-19 infection.

When a virus invades the human body, the body produces specific antibodies for defense, of which the specific antibody IgM is the first to be produced for early defense, followed by the production of IgG antibodies. Serologic testing is used to indirectly determine the presence or absence of the virus and the status of the virus infection by detecting the presence and level of the specific antibodies IgM and IgG in blood samples. Antibodies in the patient's body are the most direct and promising candidate for the treatment of COVID-19.

After the outbreak of COVID-19, many pharmaceutical companies laid out a pipeline of COVID-19 neutralizing antibodies. Antibody drug candidates against COVID-19 are mainly categorized into two groups. One is monoclonal antibodies that relieve symptoms, especially the cytokine storm caused by COVID-19, such as monoclonal antibodies targeting IL-1, IL-6, IL-8, or GM-CSF; and the second category is neutralizing antibodies that can stop neocoronaviruses from infecting cells, including combinations of monoclonal antibodies targeting the spiny proteins (S proteins). Chinese scholars have developed antibody combination therapies, also known as "cocktail therapies". Antibody combination therapy combines multiple antibodies in order to effectively treat the prevailing virus or even mutated strains of the virus. By selecting two antibodies with different targets, the combination therapy is able to maximize its effectiveness against possible future mutations. Clinical results have demonstrated the significant therapeutic effects of this antibody combination therapy.

Creative Biolabshas a wealth of knowledge and experience in premade antibody library screening. We would be happy to share with you our knowledge and experience in premade phage displayed human antibody library construction and Coronavirus (COVID-19) antibody discovery.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: